PMID- 33176882 OWN - NLM STAT- MEDLINE DCOM- 20210618 LR - 20231112 IS - 1757-6512 (Electronic) IS - 1757-6512 (Linking) VI - 11 IP - 1 DP - 2020 Nov 11 TI - Human menstrual blood-derived stem cells mitigate bleomycin-induced pulmonary fibrosis through anti-apoptosis and anti-inflammatory effects. PG - 477 LID - 10.1186/s13287-020-01926-x [doi] LID - 477 AB - BACKGROUND: Idiopathic pulmonary fibrosis is a kind of diffuse interstitial lung disease, the pathogenesis of which is unclear, and there is currently a lack of good treatment to improve the survival rate. Human menstrual blood-derived mesenchymal stem cells (MenSCs) have shown great potential in regenerative medicine. This study aimed to explore the therapeutic potential of MenSCs for bleomycin-induced pulmonary fibrosis. METHODS: We investigated the transplantation of MenSCs in a pulmonary fibrosis mouse model induced by BLM. Mouse was divided into three groups: control group, BLM group, MenSC group. Twenty-one days after MenSC transplantation, we examined collagen content, pathological, fibrosis area in the lung tissue, and the level of inflammatory factors of serum. RNA sequence was used to examine the differential expressed gene between three groups. Transwell coculture experiments were further used to examine the function of MenSCs to MLE-12 cells and mouse lung fibroblasts (MLFs) in vitro. RESULTS: We observed that transplantation of MenSCs significantly improves pulmonary fibrosis mouse through evaluations of pathological lesions, collagen deposition, and inflammation. Transwell coculturing experiments showed that MenSCs suppress the proliferation and the differentiation of MLFs and inhibit the apoptosis of MLE-12 cells. Furthermore, antibody array results demonstrated that MenSCs inhibit the apoptosis of MLE-12 cells by suppressing the expression of inflammatory-related cytokines, including RANTES, Eotaxin, GM-CSF, MIP-1gamma, MCP-5, CCL1, and GITR. CONCLUSIONS: Collectively, our results suggested MenSCs have a great potential in the treatment of pulmonary fibrosis, and cytokines revealed in antibody array are expected to become the target of future therapy of MenSCs in clinical treatment of pulmonary fibrosis. FAU - Chen, Xin AU - Chen X AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. FAU - Wu, Yi AU - Wu Y AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. FAU - Wang, Yanling AU - Wang Y AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. FAU - Chen, Lijun AU - Chen L AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. FAU - Zheng, Wendi AU - Zheng W AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. FAU - Zhou, Sining AU - Zhou S AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. FAU - Xu, Huikang AU - Xu H AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. FAU - Li, Yifei AU - Li Y AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. FAU - Yuan, Li AU - Yuan L AD - Innovative Precision Medicine (IPM) Group, Hangzhou, 311215, China. FAU - Xiang, Charlie AU - Xiang C AUID- ORCID: 0000-0002-9193-3900 AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310027, People's Republic of China. charliexiang@126.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201111 PL - England TA - Stem Cell Res Ther JT - Stem cell research & therapy JID - 101527581 RN - 0 (Anti-Inflammatory Agents) RN - 11056-06-7 (Bleomycin) SB - IM MH - Animals MH - Anti-Inflammatory Agents MH - *Bleomycin/toxicity MH - Humans MH - Menstruation MH - Mice MH - *Pulmonary Fibrosis/chemically induced/therapy MH - Stem Cells PMC - PMC7656201 OTO - NOTNLM OT - Apoptosis OT - Bleomycin OT - Inflammation OT - Menstrual blood-derived mesenchymal stem cells OT - Pulmonary fibrosis OT - Stem cell transplantation therapy COIS- The authors declare that they have no conflict of interest. EDAT- 2020/11/13 06:00 MHDA- 2021/06/22 06:00 PMCR- 2020/11/11 CRDT- 2020/11/12 05:31 PHST- 2020/06/25 00:00 [received] PHST- 2020/09/04 00:00 [accepted] PHST- 2020/11/12 05:31 [entrez] PHST- 2020/11/13 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2020/11/11 00:00 [pmc-release] AID - 10.1186/s13287-020-01926-x [pii] AID - 1926 [pii] AID - 10.1186/s13287-020-01926-x [doi] PST - epublish SO - Stem Cell Res Ther. 2020 Nov 11;11(1):477. doi: 10.1186/s13287-020-01926-x.